Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 9 de 9
Filtrar
Más filtros

País/Región como asunto
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Rev Esp Cardiol (Engl Ed) ; 77(3): 243-253, 2024 Mar.
Artículo en Inglés, Español | MEDLINE | ID: mdl-37516312

RESUMEN

INTRODUCTION AND OBJECTIVES: Remote monitoring (RM) of cardiac implantable electronic devices (CIEDs) is considered more reliable, efficient, and safer than conventional in-person follow-up. However, the implementation of RM is still suboptimal. This study aimed to analyze the impact of the COVID-19 pandemic on the rates of CIED implants and RM activations in Spain. METHODS: The COVID-19 RM Spain Registry was used to analyze the monthly number of all CIED implantations and RM activations from January 2018 to December 2021. A descriptive analysis was performed using aggregated data from the five major CIED manufacturers. RESULTS: A total of 205 345 CIEDs were recorded. The number of implants decreased sharply (48.2%) during the pandemic lockdown (March-June 2020) but gradually increased thereafter, compensating for the previous reduction. However, pacemakers and implantable cardiac defibrillators (ICD) showed an aggregate loss of 7% and 3%, respectively, from the annual average during 2020-2021. In contrast, cardiac resynchronization therapy defibrillators (CRT-D) increased by 17%, and pacemakers (CRT-P) by 4.5% over the 2-year period. The percentage of RM activations increased from 24.5% in 2018 to 49.0% in 2021, with a sharp increase during the lockdown. The RM activation rates consistently increased during the lockdown for all devices: pacemakers (14.4% vs 37.2%; P <.001); ICD (75.6% vs 94.2%; P <.001); CRT-D/CRT-P (68.6-44.2% vs 81.6-61%; P <.001), and implantable loop recorders (50.2% vs 68.7%; P <.001). CONCLUSIONS: The significant decline in implants during the lockdown gradually recovered, except for pacemakers and ICD. However, the COVID-19 pandemic boosted RM for all CIEDs in Spain.


Asunto(s)
COVID-19 , Terapia de Resincronización Cardíaca , Desfibriladores Implantables , Marcapaso Artificial , Humanos , Pandemias , COVID-19/epidemiología , Control de Enfermedades Transmisibles
2.
Endoscopy ; 44(4): 408-21, 2012 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-22438152

RESUMEN

This article expresses the current view of the European Society of Gastrointestinal Endoscopy (ESGE) about radiation protection for endoscopic procedures, in particular endoscopic retrograde cholangiopancreatography (ERCP). Particular cases, including pregnant women and pediatric patients, are also discussed. This Guideline was developed by a group of endoscopists and medical physicists to ensure that all aspects of radiation protection are adequately dealt with. A two-page executive summary of evidence statements and recommendations is provided. The target readership for this Guideline mostly includes endoscopists, anesthesiologists, and endoscopy assistants who may be exposed to X-rays during endoscopic procedures.


Asunto(s)
Colangiopancreatografia Retrógrada Endoscópica/instrumentación , Colangiopancreatografia Retrógrada Endoscópica/normas , Exposición Profesional/análisis , Seguridad del Paciente/normas , Monitoreo de Radiación/normas , Protección Radiológica/normas , Adulto , Niño , Pancreatocolangiografía por Resonancia Magnética , Endosonografía , Femenino , Filtración , Fluoroscopía/métodos , Fluoroscopía/normas , Personal de Salud , Humanos , Educación del Paciente como Asunto , Embarazo , Complicaciones del Embarazo/diagnóstico , Garantía de la Calidad de Atención de Salud/legislación & jurisprudencia , Dosis de Radiación , Monitoreo de Radiación/métodos , Suiza
4.
An Sist Sanit Navar ; 26(2): 277-82, 2003.
Artículo en Español | MEDLINE | ID: mdl-12951622

RESUMEN

The intramyocardial dissecting haematoma is an unusual rupture of the left ventricular wall, complicating acute myocardial infarction. The mechanism is an hemorrhagic dissection among the spiral myocardial fibres creating a neocavitation limited by the myocardium. It appears in 9% of left ventricular wall ruptures, complicating acute myocardial infarction. Diagnosis is often difficult and in most of the cases it is post-mortem. We present the case report of a 69 year old patient who suffered a posterolateral acute myocardial infarction treated with primary PTCA/Stent plus AAS, clopidogrel, unfractioned heparin bolus and GP IIb- IIIa inhibitors. In the following few hours he suffered this unusual form of cardiac rupture that took him into cardiogenic shock and finally led to his death. The pathophysiology, diagnosis and management of this lethal complication of acute myocardial infarction (90% mortality in the medically treated group) which is only effectively treated by surgery are also reviewed.


Asunto(s)
Rotura Cardíaca Posinfarto/patología , Ventrículos Cardíacos/patología , Anciano , Electrocardiografía , Resultado Fatal , Rotura Cardíaca Posinfarto/diagnóstico , Rotura Cardíaca Posinfarto/terapia , Humanos , Masculino
5.
Aliment Pharmacol Ther ; 34(5): 544-54, 2011 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-21722149

RESUMEN

BACKGROUND: Low thiopurine-methyl-transferase (TPMT) activity and high 6-thioguanine-nucleotide (6TGN) concentrations have been linked to therapeutic success in inflammatory bowel disease patients treated with thiopurines; however, this has not been implemented in clinical practice. AIM: To identify a therapeutic threshold value for TPMT or 6TGN concentrations, and their capability to predict treatment safety and efficacy. METHODS: Prospective multicentre study including steroid-resistant/dependent patients starting thiopurines. The TPMT activity was determined at inclusion (>5 U/mL required). Azathioprine metabolites [6TGN, 6-methyl-mercaptopurine ribonucleotides (6MMP), and 6TGN/6MMP and 6TGN/TPMT ratios] were periodically monitored during steroid tapering and after withdrawal for 6 months or until a new flare occurred. RESULTS: A total of 113 patients were analysed (62% clinical response). Areas under the receiver operating characteristic (ROC) curve (AUC) relating clinical response and metabolite levels at 2, 4 and 6 months after steroid withdrawal were less than 0.7. The AUCs relating final response and initial TPMT activity or metabolite concentrations at 2, 4, 8 and 16 weeks after starting thiopurines were less than 0.7. No cut-off point with worthwhile sensitivity/specificity was found. Eight (7%) patients developed thiopurine-related toxicity that could not be linked to TPMT activity or 6TGN levels. CONCLUSIONS: Our results do not support determination of TPMT activity or 6TGN concentrations to predict treatment outcome, and no useful serum metabolites threshold value to adjust the drug's dose was identified.


Asunto(s)
Azatioprina/sangre , Inmunosupresores/uso terapéutico , Enfermedades Inflamatorias del Intestino/tratamiento farmacológico , Mercaptopurina/análogos & derivados , Mercaptopurina/administración & dosificación , Metiltransferasas/sangre , Adolescente , Adulto , Anciano , Área Bajo la Curva , Biomarcadores/metabolismo , Relación Dosis-Respuesta a Droga , Femenino , Nucleótidos de Guanina/sangre , Humanos , Enfermedades Inflamatorias del Intestino/enzimología , Masculino , Persona de Mediana Edad , Estudios Prospectivos , Curva ROC , Tionucleótidos/sangre , Resultado del Tratamiento , Adulto Joven
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA